Sermorelin dose-response findings and what they leave open
Purity across our Sermorelin samples ranged from 93.2% to 98.5%. Here is the context.
Study SummaryAlso known as: Pralmorelin
A synthetic GH secretagogue used diagnostically in Japan and widely sold as a research compound elsewhere.
GHRP-2 is classified as a growth-hormone-releasing peptide. Its current development status is: approved in japan for diagnostics. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.
The Peptide Institute tracks GHRP-2 because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Independent Testing
Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.
98.4% average purity across 2 samples
Purity & Testing 99 Transparency 90 Samples 2 89 View company98.7% average purity across 1 sample
Purity & Testing 99 Transparency 72 Samples 1 85 View company97% average purity across 1 sample
Purity & Testing 91 Transparency 66 Samples 1 74 View companyComparative effects of GHRP-2 on metabolic endpoints
One of the more methodologically careful entries in the GHRP-2 literature.
GHRP-2: dose-ranging efficacy and safety findings
Adds to the GHRP-2 evidence base without resolving the central question of human efficacy.
Immunogenicity and stability profile of GHRP-2
Characterises GHRP-2 activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.
Laboratory verification of GHRP-2 products across the companies we index.
Purity across our Sermorelin samples ranged from 93.2% to 98.5%. Here is the context.
Study SummaryPurity across our Sermorelin samples ranged from 93.2% to 98.5%. Here is the context.
Study SummaryA close reading of the Sermorelin evidence, without the marketing layer.
ResearchThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.